What we do Norris Medicines Ltd manufactures pharmaceutical formulations including tablets, capsules, liquid orals, ointments, ampoules and vials primarily serving the healthcare sector. |
Founded in 1,990 |
Market share Recognized as a leading Indian manufacturer of injections and medicinal formulations with WHO GMP approved facilities, holding a steady domestic presence. |
Problem solved Provides reliable and quality sterile and non-sterile pharmaceutical dosage forms addressing healthcare needs for various therapeutic areas including diabetic, cardiac, dental, and anti-malarial products. |
Top clients or who we serve Serves healthcare providers and the pharmaceutical distribution network, mainly B2B within India. |
Key management Mr. Vimal D. Shah (Executive Director), Mr. Iqubal Patel (CFO), Ms. Priyanka Lohiya (Company Secretary) |
Our journey and innovations Started in 1990; expanded from non-sterile to sterile products. Launched diabetic, cardiac, dental, and new molecule formulations over years. Upgraded sterile injectable plant to international standards. |
Where we operate Operations centered in India with manufacturing at GIDC, Ankleshwar, Gujarat; no mention of exports. |
Top products or what we offer Tablets, capsules, liquid orals, topical ointments, sterile ampoules and vials; specialties include diabetic, cardiac, dental and anti-malarial medicines. |
Top brands - |
Raw materials needed Pharmaceutical bulk drugs and excipients used for formulation of tablets, injections, and ointments. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mostly recurring from pharmaceutical formulations manufacturing and sales. |
Our industry position Established manufacturer with WHO GMP certification; competitive presence in Indian sterile and non-sterile pharmaceutical segments. |
Financial highlights FY 2024-25 revenue Rs 5.82 crore; net loss Rs 1.24 crore; minor growth compared to previous year; currently facing financial challenges. |
Geographical revenue split - |
Order book - |
Whats driving growth Upgraded manufacturing capacity, expanded product portfolio in key therapeutic areas, and sustained demand for medicinal formulations. |
Our future plans Focus on compliance enhancement, capacity utilization, and business stabilization; no major expansion due to current financial position. |
Our green promise - |
Our people and values Maintains professional governance and committed employee base emphasizing safety, compliance, and ethical practices. |
Key challenges ahead Financial losses, regulatory compliance gaps, and strengthening internal controls amid competitive pharmaceutical market. |
Interesting facts Company has WHO GMP approved plants and has upgraded sterile injectable manufacturing to international standards. |
Risks and strategy Managing regulatory compliance, financial turnaround and internal controls; strategy includes process improvements and asset safeguard. |
